| Literature DB >> 34305423 |
Alan Joel Ruiz-Padilla1, Angel Josabad Alonso-Castro1, Mónica Preciado-Puga2, Ariadna Irais González-Núñez1, José Lorenzo González-Chávez1, Yeniley Ruiz-Noa3, Miriam Ortiz-Cortes4, Lorena Michele Brennan-Bourdon5, Martha Alicia Deveze-Álvarez1.
Abstract
BACKGROUND: The aim of this study was to assess the frequency of allopathic and complementary medicine use for preventing the infection with SARS-CoV-2 in Mexico. A descriptive and cross-sectional study was conducted using an online questionnaire among general adult population (n = 16,724) of the 32 Mexican states from March to November 2020.Entities:
Keywords: COVID-19; Complementary medicine; Cross-sectional study; Self-medication
Year: 2021 PMID: 34305423 PMCID: PMC8280660 DOI: 10.1016/j.jsps.2021.07.009
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Factors associated with the use of allopathic and complementary medicine for the prevention of SARS-CoV-2.
| Characteristic | TOTAL N = 16724 | Use of any product Frequency [n (%)] | |||
|---|---|---|---|---|---|
| YES N = 7075 (42.9) | NO n = 9649 (57.1) | OR (95% CI) | |||
| Age group, years (mean ± SD) | 29.5 ± 12.5 | 27.7 ± 11.2 | – | ||
| 18–25 | 7793 (46.6) | 3985 (41.3) | |||
| greater than 25 | 8931 (53.4) | 3267 (46.2) | 5664 (58.7) | ||
| Gender | |||||
| Female | 10,345 (61.9) | 5696 (59) | |||
| Male | 6379 (38.1) | 2426 (34.3) | 3953 (41) | ||
| Education | |||||
| College-postgraduate | 12,041 (72) | 4916 (69.5) | 7125 (73.8) | 1 | Ref. |
| High school | 1096 (6.6) | 447 (6.3) | 649 (6.7) | 0.978 | 0.998 (0.880–1.132) |
| Elementary and middle school | 3587 (21.4) | 1875 (19.4) | |||
| Socioeconomic status | |||||
| Low | 3949 (23.6) | 2230 (23.1) | |||
| Middle | 4506 (26.9) | 1930 (27.3) | 2576 (26.7) | 0.125 | 1.059 (0.984–1.140) |
| High | 8269 (49.4) | 3426 (48.4) | 4843 (50.2) | 1 | Ref. |
| Marital status | |||||
| Married/cohabitant | 5324 (31.8) | 2628 (27.2) | |||
| Single/divorced/widow | 11,400 (68.2) | 4379 (61.9) | 7021 (72.8) | ||
| Employment status | |||||
| Housewife/Employed | 14,078 (84.2) | 8040 (83.3) | |||
| Unemployed | 951 (5.7) | 475 (4.9) | |||
| Student | 1695 (10.1) | 561 (7.9) | 1134 (11.8) | 1 | Ref. |
| Comorbidity | |||||
| Yes | 3597 (21.5) | 1919 (19.9) | |||
| No | 13,127 (78.5) | 5397 (76.3) | 7730 (80.1) | ||
| Health insurance program | |||||
| None | 3964 (23.7) | 2180 (22.6) | |||
| Private | 1986 (11.9) | 855 (12.1) | 1131 (11.7) | 0.158 | 1.083 (0.971–1.207) |
| Public | 10,774 (64.4) | 4436 (62.7) | 6338 (65.7) | 1 | Ref. |
Presence of adverse reactions due the consumption of allopathic medicine for preventing SARS-CoV-2 infection among Mexican population.
| Treatment | Total | Acetaminophen | Aspirin | Ibuprofen | Dexamethasone | HCQ | CLQ | Azithromycin | Ivermectin |
|---|---|---|---|---|---|---|---|---|---|
| Time of use during the week, | |||||||||
| Daily | 1117 (24.5) | 486 (21.4) | 246 (27.7) | 149 (17.7) | 176 (26.3) | 22 (33.3) | 15 (45.5) | 46 (29.5) | 389 (24.1) |
| 1 to 2 times | 2216 (48.7) | 1166 (51.3) | 441 (49.7) | 493 (58.5) | 281 (41.9) | 29 (43.9) | 10 (30.3) | 73 (46.8) | 851 (52.6) |
| 3 to 5 times | 1221 (26.8) | 620 (27.3) | 201 (22.6) | 201 (23.8) | 213 (31.8) | 15 (22.7) | 8 (24.2) | 37 (23.7) | 377 (23.3) |
| Time of use, | |||||||||
| Less than a month | 1805 (39.6) | 1025 (45.1) | 383 (43.1) | 412 (48.9) | 313 (46.7) | 32 (48.5) | 10 (30.3) | 86 (55.1) | 446 (27.6) |
| 1 to 3 months | 1433 (31.5) | 714 (31.4) | 262 (29.5) | 224 (26.6) | 195 (29.1) | 21 (31.8) | 10 (30.3) | 43 (27.6) | 535 (33.1) |
| More than 3 months | 1316 (28.9) | 533 (23.5) | 243 (27.4) | 207 (24.6) | 162 (24.2) | 13 (19.7) | 13 (39.4) | 27 (17.3) | 336 (39.3) |
| Recommended by, | |||||||||
| Physician | 894 (19.6) | 572 (25.2) | 226 (25.5) | 230 (27.3) | 129 (19.3) | 23 (34.8) | 10 (30.3) | 75 (48.1) | 230 (14.2) |
| Own initiative | 1544 (33.9) | 690 (30.4) | 223 (25.1) | 209 (24.8) | 242 (36.1) | 15 (22.7) | 8 (24.2) | 19 (12.2) | 605 (37.4) |
| Relative/friend | 1504 (33) | 719 (31.6) | 288 (32.4) | 297 (35.2) | 211 (21.5) | 16 (24.2) | 8 (24.2) | 46 (29.5) | 583 (36.1) |
| Drugstore | 126 (2.8) | 83 (3.7) | 20 (2.3) | 35 (4.2) | 23 (3.4) | 0 | 0 | 0 | 15 (0.9) |
| Herbalist | 63 (1.4) | 19 (0.8) | 9 (1) | 9 (1.1) | 11 (1.6) | 1 (1.5) | 1 (3) | 1 (0.6) | 28 (1.7) |
| Media | 423 (9.3) | 189 (8.3) | 122 (13.7) | 63 (7.5) | 54 (8.1) | 11 (16.7) | 6 (18.2) | 15 (9.6) | 156 (9.6) |
| Adverse reactions | 249 (5.5) | 122 (5.4) | 81 (9.1) | 54 (6.4) | 56 (8.4) | 14 (21.2) | 5 (15.2) | 11 (8.5) | 22 (14.1) |
| HCQ: Hydroxychloroquine. CLQ: Chloroquine | |||||||||
Presence of adverse reactions due the consumption of complementary medicine for preventing SARS-CoV-2 infection among Mexican population.
| Treatment | Total | Chlorine dioxide | Transfer factor | Green tea | Zinc | Vitamin C | Lemon | Curcuma | Ginger | Propolis | Ginseng | Garcinia | Echinacea |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time of use during the week, | |||||||||||||
| Daily | 1491 (31.5) | 142 (42.1) | 43 (32.1) | 389 (24.1) | 281 (42.2) | 1021 (31.4) | 668 (28.2) | 258 (31.4) | 450 (27.4) | 200 (29) | 82 (32) | 28 (45.9) | 89 (38.5) |
| 1 to 2 times | 2181 (46.1) | 114 (33.8) | 53 (39.6) | 851 (52.6) | 225 (33.8) | 1529 (47) | 1179 (49.7) | 349 (42.5) | 795 (48.4) | 330 (47.9) | 119 (46.5) | 21 (34.4) | 79 (34.2) |
| 3 to 5 times | 1059 (22.4) | 81 (24) | 38 (28.4) | 377 (23.3) | 160 (24) | 702 (21.6) | 525 (22.1) | 214 (26.1) | 399 (24.3) | 159 (23.1) | 55 (21.5) | 12 (19.7) | 63 (27.3) |
| Time of use, | |||||||||||||
| Less than a month | 1546 (32.7) | 129 (38.3) | 26 (19.4) | 446 (27.6) | 175 (26.3) | 1034 (31.8) | 742 (31.3) | 158 (19.2) | 451 (27.4) | 172 (25) | 55 (21.5) | 18 (29.5) | 55 (23.8) |
| 1 to 3 months | 1641 (34.7) | 107 (31.8) | 59 (44) | 535 (33.1) | 230 (34.5) | 1162 (35.7) | 767 (32.3) | 280 (34.1) | 543 (33) | 255 (37) | 91 (35.5) | 19 (31.1) | 81 (35.1) |
| More than 3 months | 1544 (22.4) | 101 (30) | 49 (36.6) | 636 (39.3) | 261 (39.2) | 1056 (32.5) | 863 (36.4) | 383 (46.6) | 650 (39.5) | 262 (38) | 110 (43) | 24 (39.3) | 95 (41.1) |
| Recommended by, | |||||||||||||
| Physician | 807 (17.1) | 73 (21.7) | 36 (26.9) | 230 (14.2) | 200 (30) | 659 (20.3) | 309 (13) | 117 (14.3) | 226 (13.7) | 97 (14.1) | 48 (18.8) | 22 (36.1) | 47 (20.3) |
| Own initiative | 1802 (38.1) | 61 (18.1) | 48 (35.8) | 605 (37.4) | 221 (33.2) | 1254 (38.6) | 933 (39.3) | 362 (44.1) | 639 (38.9) | 249 (36.1) | 115 (44.9) | 22 (36.1) | 115 (49.8) |
| Relative/friend | 1539 (32.5) | 157 (46.6) | 29 (21.6) | 583 (36.1) | 181 (27.2) | 1024 (31.5) | 845 (35.6) | 222 (27) | 568 (34.5) | 236 (34.6) | 56 (21.9) | 9 (14.8) | 51 (22.1) |
| Drugstore | 58 (1.2) | 3 (0.9) | 5 (3.7) | 15 (0.9) | 7 (1.1) | 42 (1.3) | 19 (0.8) | 4 (0.5) | 9 (0.5) | 7 (1) | 7 (2.7) | 0 | 3 (0.9) |
| Herbalist | 80 (1.7) | 3 (0.9) | 2 (1.5) | 28 (1.7) | 11 (1.7) | 30 (0.9) | 31 (1.3) | 17 (2.1) | 41 (2.5) | 24 (3.5.) | 12 (4.7) | 4 (6.6) | 15 (6.5) |
| Media | 445 (9.4) | 40 (11.9) | 14 (10.4) | 156 (9.6) | 46 (6.9) | 243 (7.5) | 235 (9.9) | 99 (12.1) | 161 (9.8) | 76 (11) | 18 (7) | 4 (6.6) | 3 (1.3) |
| Adverse reactions, | 227 (4.8) | 35 (10.4) | 13 (9.7) | 53 (3.3) | 29 (4.4) | 113 (3.5) | 128 (5.4) | 4 (4.9) | 75 (4.6) | 45 (6.5) | 30 (11.7) | 4 (6.6) | 11 (4.8) |